SG Americas Securities
STLN

SG Americas Securities’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

SG Americas Securities’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43K Sell
14,098
-2,039
-13% -$6.25K ﹤0.01% 3037
2025
Q4 		$57K Sell
16,137
-12,208
-43% -$45.3K ﹤0.01% 3340
2025
Q3 		$99K Buy
+28,345
New +$97.1K ﹤0.01% 3090
2023
Q2 		– Sell
-14,740
Closed -$10K – 3155
2023
Q1 		$10K Buy
+14,740
New +$18.8K ﹤0.01% 3186

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's STLN Position: Q1 2026 in Review

SG Americas Securities reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 13% in Q1 2026, selling an estimated $6.25K and leaving 14,098 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #3037.

SG Americas Securities first reported a position in STLN in Q1 2023 and has held it in 4 quarters since. The position peaked at $99K in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • SG Americas Securities held 14,098 shares of Starling Oncology Institute, Inc. Common Stock worth $43K as of Q1 2026.
  • SG Americas Securities sold 2,039 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $6.25K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #3037 holding.
  • SG Americas Securities first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2023 and has held it in 4 quarters since.
  • SG Americas Securities's Starling Oncology Institute, Inc. Common Stock position peaked at $99K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.